At what stage of breast cancer do you need to take neratinib/neratinib (He Li'an)

Neratinib/neratinib (Neratinib) is mainly used to treat patients with early-stage HER2-positive breast cancer and is used to further reduce the risk of recurrence after completing standard adjuvant therapy (such as trastuzumab therapy). It is usually recommended to start using neratinib within 1 year after the end of postoperative adjuvant therapy to maximize the benefit of its extended treatment. The drug is mostly suitable for patients with stage II or III HER2-positive breast cancer, especially patients with hormone receptor-positive (HR+) characteristics. Because this group of people has a relatively high risk of long-term recurrence, neratinib can significantly delay the recurrence process and improve disease-free survival.

For patients with stage I early breast cancer, if the lesions are small and the risk is low, extended treatment with neratinib is generally not recommended. For patients with stage IV or metastatic breast cancer, neratinib is usually used in combination with other chemotherapy drugs or targeted drugs, such as with capecitabine, to control advanced lesions and prolong survival. As a pan-HER inhibitor, neratinib's effect is not limited to HER2, but can also inhibit HER1 (EGFR) and HER4 signals at the same time, so it may also bring potential benefits to tumor types driven by multiple pathways.

In treatment guidelines, neratinib is often recommended as an "extended adjuvant treatment" program for patients who have completed12 months of trastuzumab treatment, and the treatment course generally lasts for 1 year. The study results show that patients with HR-positive benefit more significantly from the use of neratinib, especially in the case of postoperative residual disease or positive axillary lymph nodes, the recurrence rate is reduced more significantly.

In general, neratinib is suitable for patients with stage II to III HER2-positive and HR-positive breast cancer. The main goal is to prevent postoperative recurrence and metastasis. Since drugs have certain adverse reactions (such as diarrhea, nausea, etc.), doctors usually give auxiliary antidiarrheal drugs at the beginning of treatment and adjust the dosage according to the patient's tolerance.

Reference materials:https://en.wikipedia.org/wiki/Neratinib